Show simple item record

dc.contributor.authorRoberts, Darren L
dc.contributor.authorO'Dwyer, Sarah T
dc.contributor.authorStern, Peter L
dc.contributor.authorRenehan, Andrew G
dc.date.accessioned2015-05-19T14:21:04Zen
dc.date.available2015-05-19T14:21:04Zen
dc.date.issued2015-04-13en
dc.identifier.citationGlobal gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines. 2015: Oncotargeten
dc.identifier.issn1949-2553en
dc.identifier.pmid25929336en
dc.identifier.urihttp://hdl.handle.net/10541/554175en
dc.description.abstractPseudomyxoma peritonei (PMP) is a rare tumor of appendiceal origin. Treatment is major cytoreductive surgery but morbidity is high. PMP is considered chemo-resistant; its molecular biology is understudied; and presently, there is no platform for pre-clinical drug testing. Here, we performed exon array analysis from laser micro-dissected PMP tissue and normal colonic epithelia. The array analysis identified 27 up-regulated and 34 down-regulated genes: candidate up-regulated genes included SLC16A4, DSC3, Aldolase B, EPHX4, and ARHGAP24; candidate down-regulated genes were MS4A12, TMIGD1 and Caspase-5. We confirmed differential expression of the candidate genes and their protein products using in-situ hybridization and immuno-histochemistry. In parallel, we established two primary PMP cell lines, N14A and N15A, and immortalized with an SV40 T-antigen lentiviral vector. We cross-checked for expression of the candidate genes (from the array analyses) using qPCR in the cell lines and demonstrated that the gene profiles were distinct from those of colorectal tumor libraries and commonly used colon cell lines. N14A and N15A were responsiveness to mitomycin and oxaliplatin. This study characterizes global gene expression in PMP, and the parallel development of the first immortalized PMP cell lines; fit for pre-clinical testing and PMP oncogene discovery.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Oncotargeten
dc.titleGlobal gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.en
dc.typeArticleen
dc.contributor.departmentImmunology Group, Paterson Institute for Cancer Research, The University of Manchester, Manchesteren
dc.identifier.journalOncotargeten
html.description.abstractPseudomyxoma peritonei (PMP) is a rare tumor of appendiceal origin. Treatment is major cytoreductive surgery but morbidity is high. PMP is considered chemo-resistant; its molecular biology is understudied; and presently, there is no platform for pre-clinical drug testing. Here, we performed exon array analysis from laser micro-dissected PMP tissue and normal colonic epithelia. The array analysis identified 27 up-regulated and 34 down-regulated genes: candidate up-regulated genes included SLC16A4, DSC3, Aldolase B, EPHX4, and ARHGAP24; candidate down-regulated genes were MS4A12, TMIGD1 and Caspase-5. We confirmed differential expression of the candidate genes and their protein products using in-situ hybridization and immuno-histochemistry. In parallel, we established two primary PMP cell lines, N14A and N15A, and immortalized with an SV40 T-antigen lentiviral vector. We cross-checked for expression of the candidate genes (from the array analyses) using qPCR in the cell lines and demonstrated that the gene profiles were distinct from those of colorectal tumor libraries and commonly used colon cell lines. N14A and N15A were responsiveness to mitomycin and oxaliplatin. This study characterizes global gene expression in PMP, and the parallel development of the first immortalized PMP cell lines; fit for pre-clinical testing and PMP oncogene discovery.


This item appears in the following Collection(s)

Show simple item record